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Abstract Gastroenteropancreatic (GEP) endocrine tu-
mors (ETs) are neoplasms showing different hormonal
profiles and different clinical and prognostic features,
which depend consistently on the site of origin. Histo-
logical features and general endocrine markers do not
differentiate tumors in relation to their location, making it
difficult to establish the site of origin of a GEP ET that
has metastasized to the liver or lymph nodes. A site-
specific marker would be particularly useful in the ex-
amination of small specimens where there is not sufficient
material for an extensive study of the hormonal expres-
sion. CDX2 is a transcription factor that has been recently
proposed as a marker of intestinal adenocarcinomas. Our
aim was to evaluate the immunohistochemical expression
of CDX2 in normal tissues and in 184 formalin-fixed and
paraffin-embedded ETs to verify whether it could be used
to identify intestinal ETs with a high degree of sensitivity
and specificity. Of these cases, 154 were primary tumors
(99 GEP and 55 non-GEP tumors), 101 were well-dif-
ferentiated endocrine tumors, and 53 were poorly differ-
entiated endocrine carcinomas (PDECs). Of the cases, 30
were metastases from differently located ETs. Nuclear
CDX2 immunoreactivity was found in all EC-cells (se-
rotonin-producing cells), in about 10% of G-cells (gastrin-
producing cells), in about 30% of GIP-cells (gastric in-
hibitory peptide cells) and in a few motilin-positive cells
of the normal intestinal mucosa, while other gastrointes-
tinal endocrine cell types were CDX2 negative. All
midgut EC-cell tumors, their metastases, and two of three
pancreatic EC-cell ETs were diffusely and intensely
CDX2 positive. The other GEP ETs, their metastases, as
well as the non-GEP ETs, were all CDX2 negative, with
the exception of four PDECs, five gastrinomas and one
pheochromocytoma, which were only focally positive.
We conclude that CDX2 may be considered a sensitive
and specific marker of midgut EC-cells and EC-cell tu-
mors, and its expression may be useful in the diagnosis of
metastases from occult ETs.
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Introduction
Cdx2 is a homeobox gene that has been recently found to
play a role in the development and differentiation of
mammalian intestine [8, 24, 25]. The gene codifies a
transcription factor protein named CDX2 [5], which in-
creases the expression of several gene products associated
with mature intestinal epithelial cells [30]. This complex
machinery of sequentially activated genes seems to de-
crease cellular replication and induce differentiation to
mature intestinal epithelium [30].
All recent published papers regarding the role and
expression of CDX2 in intestinal epithelium have focused
their attention on the exocrine component of the bowel
mucosa. However, it is well known that there are several
scattered endocrine cell types along the gut that, together
with those located in the pancreas, form a large endocrine
organ, generally referred to as the gastroenteropancreatic
(GEP) endocrine system [27]. This system is remarkably
heterogeneous and is composed of as many as 15 highly
specialized endocrine cells, which show different hor-
monal profiles, physiological functions and site distribu-
tion [13, 27]. To the best of our knowledge, it is not
known whether various endocrine cell types of the gut and
pancreas express the CDX2 protein.
GEP endocrine tumors (ETs) form a heterogeneous
group of neoplasms showing different hormonal profiles
and different morphological, clinical and prognostic fea-
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tures, depending on the site of origin [13, 26]. According
to the World Health Organization classification of ETs
[27], pure endocrine neoplasms are separated into two
main categories: well-differentiated endocrine tumors
(WDETs) and poorly differentiated endocrine carcinomas
(PDECs). In histological preparations, PDECs are easily
distinguished from WDETs because they show solid
sheets composed of cells with high-grade atypia, hyper-
chromatic nuclei, a high nuclear/cytoplasmic ratio, a high
mitotic rate and extensive necrosis. In contrast, WDETs
are generally formed by uniform small/medium-sized
cells with regularly shaped nuclei, arranged in trabeculae
or solid nests, with low or no mitotic activity and no
necrosis. The histopathological features do not differen-
tiate tumors in relation to the site of origin, with the only
exception of duodenal somatostatin-producing D-cell
neoplasms, which show a prevalent pseudoglandular
pattern of growth [6]. In routine surgical pathology
practice, GEP ETs are often first discovered as liver or
lymph-node metastases coming from an occult primary
neoplasm. The diagnosis is frequently made on a small
specimen, such as a needle biopsy, and there is often
insufficient material to perform a complete immunohis-
tochemical hormonal profile, which may be “per se” a
good indicator of the primary tumor site (e.g., insulin for a
pancreatic tumor). The endocrine nature of neoplasms is
confirmed by the expression of general endocrine mark-
ers, such as chromogranins, synaptophysin and neuron-
specific enolase, which, however, are not useful for
identifying the location of the primary tumor. The pres-
ence of a clinical endocrine syndrome may help to iden-
tify the site of origin of a GEP tumor [27]. However,
several neoplasms are nonfunctioning at a clinical level,
and their identification is, therefore, frequently difficult.
It has recently been suggested that CDX2 protein ex-
pression is an important marker of colorectal adenocar-
cinomas [2, 31], and it seems to be particularly useful for
the differential diagnosis of primary lung adenocarcino-
mas and lung metastases from intestinal adenocarcino-
mas. As far as we aware, apart from GEP hormones, there
is no other specific marker for intestinal endocrine tu-
mors, and the expression of CDX2 protein in GEP en-
docrine neoplasms has only been investigated in prelim-
inary studies [3, 14].
The aim of the present investigation was to evaluate
the expression of CDX2 in normal GEP endocrine cells
and in a large series of intestinal and extra-intestinal en-
docrine tumors to verify whether CDX2 may be used as a
marker of tumors of intestinal origin.
Materials and methods
Cases
The material used in this study was obtained from the files of the
Department of Pathology of the Ospedale di Circolo-University of
Insubria in Varese. The material consisted of 184 endocrine tumors
from different sites, which are listed in Table 1, Table 2 and Ta-
ble 3. Of the cases, 154 were primary tumors, while 30 neoplasms
represented metastases to the liver (6 cases), lymph nodes (22
Table 1 Main clinicopathological features and CDX2 expression
in gastroenteropancreatic well-differentiated endocrine tumors.
WHOWorld Health Organization, B benign behavior, UB uncertain
behavior, C well-differentiated carcinoma, type 1 gastric histamine-
producing enterochromaffin-like (ECL)-cell tumor associated with
chronic atrophic gastritis, type 3 sporadic gastric ECL-cell tumor,
G-cell gastrin-producing cell, D-cell somatostatin-producing cell,
GP gangliocytic paraganglioma, EC-cell serotonin-producing cell,
L-cell glicentin-producing cell, A-cell glucagon-producing cell, PP-
cell pancreatic polypeptide-producing cell
Site n WHO
classification
Tumor Sex Age (years) Size (cm) Metas-
tases
CDX2
B UB C Type F/M Mean Range Mean Range Primary Metastases
Stomach 3 2 1 Type 1 3/0 71 64–78 1.5 0.5–2 0/3 0/3
3 3 Type 3 1/2 41 26–56 2.4 2–2.8 3/3 0/3 0/3
Duodenum 4 4 G-cell 1/3 54.5 46–63 0.7 0.5–1 0/4 3/4*
3 1 1 1 D-cell 3/0 46 38–54 1.5 0.5–2.5 1/3 0/3 0/1
2 1 1 GP 0/2 57.5 36–79 3 2–4 1/2 0/2
Ileum 12 12 EC-cell 5/7 56 40–72 2.4 0.9–3 12/12 12/12 6/6
Appendix 5 5 EC-cell 2/3 71 23–96 1.7 1–2.5 0/5 5/5
Right colon 2 2 EC-cell 1/1 48 46–50 4.6 3–8 2/2 2/2 2/2
Rectum 8 6 1 1 L-cell 2/5 52 34–70 2.5 0.1–5 1/8 0/8 0/1
2 1 1 L/EC-cell 0/2 56 42–70 1.2 0.2–2 1/2 0/2
3 2 1 Undefined 2/1 52 38–72 0.2 0.1–0.3 1/2 0/3 0/1
1 1 EC-cell 0/1 45 2 0/1 0/1
Pancreas 8 8 Insulinoma 4/4 59 33–85 1.3 1–1.7 0/8 0/8
2 2 Gastrinoma 2/0 55.5 40–71 2 2–2 2/2 2/2*
5 5 A-cell 3/2 58 25–66 1.6 1.2–2.1 0/5 0/5
3 1 2 PP-cell 1/1 57.5 28–59 4.9 1.8–8 2/3 1/3
1 1 A/D-cell 1/0 37 6 1/1 0/1
3 2 1 EC-cell 2/1 62.3 50–75 2.5 2–3 1/3 2/3
1 1 VIPoma 0/1 72 5.5 0/1 0/1
1 1 Undefined 0/1 57 3.5 1/1 0/1
Total 72 27/72
(37.5%)
8/14
* Nuclear immunoreactivity was weak and focal
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cases) or omentum (2 cases). Among the primary tumors, 101 were
WDETs: 72 GEP (Table 1) and 29 non-GEP (Table 2) endocrine
neoplasms. Of the tumors, 53 were PDECs, originating in the gut
(25 cases), pancreas (2 cases) or non-GEP sites, including skin,
lung, prostate and urinary bladder (Table 3). In addition, normal
tissues from a variety of organs (gut, pancreas, thyroid, parathyroid,
adrenal gland, skin, lung, prostate, urinary bladder) were also an-
alyzed. All tissues were fixed in buffered formalin (formaldehyde
4% and acetate buffer 0.05 M) for 24 h and routinely embedded in
paraffin wax. Sections 5-mm thick were stained with hematoxylin-
eosin, alcian blue-periodic acid-Schiff and Grimelius’ silver stain
for the histopathological examination.
Immunohistochemistry
All tumors were characterized on the basis of their hormonal ex-
pression, evaluated using the antibodies listed in Table 4. CDX2
expression was detected with the monoclonal antibody CDX2–88
(Biogenex) raised against a full-length CDX2 recombinant protein.
Immunohistochemistry was performed using the avidin-biotin
complex procedure [10], while colocalization studies were per-
formed using double-label immunostains according to Mason et al.
[20] or Lan et al. [15]. Specificity controls consisted of absorption
of antibodies and antisera with 10–20 nM of their related antigens,
substitution of the primary antibody with non-immune serum of the
same species at the same dilution and use of control tissues with or
without the pertinent antigen.
The specificity and sensitivity of CDX2 immunostaining in
detecting intestinal EC-cell (serotonin-producing cell) neoplasms
was calculated as follows: specificity=true negatives/(true nega-
tives+false positives); sensitivity=true positives/(true positives+
false negatives) [2, 12]. For detecting intestinal well-differentiated
EC-cell tumors, false positives were defined as intestinal non-EC-
cell tumors or extraintestinal ETs showing CDX2 immunoreactiv-
ity, while false negatives were intestinal EC-cell neoplasms lacking
CDX2. For detecting EC-cell tumors independent of the site of
origin, false positives were defined as non-EC-cell tumors showing
CDX2 immunoreactivity, while false negatives were EC-cell neo-
plasms lacking CDX2.
Results
Normal tissue
No CDX2 immunoreactivity was observed in normal
lung, skin, prostate, urinary bladder, adrenal gland, thy-
roid gland, parathyroid glands, pancreas, esophagus or
stomach, with the only exception being areas of intestinal
metaplasia in gastric mucosa. Conversely, nuclear CDX2
immunoreactivity was found in epithelial cells of the
small and large bowel. The staining was present in all
exocrine cells of the villi and crypts, while cells of duo-
denal Brunner glands were negative or weakly stained.
Double-label immunohistochemical stains revealed that
Table 2 Main clinicopathological features and CDX2 expression in non-gastroenteropancreatic well differentiated endocrine tumors.
MTC medullary thyroid carcinoma
Site n Type Sex Age (years) Size (cm) Metastases CDX2
Mean Range Mean Range
Thyroid 10 MTC 8/2 40.8 26–62 3.6 2–5 2/10 0/10
Parathyroid 3 Hyperplasia 2/1 36 34–39 0.9 0.8–1.2 No 0/3
Carotid body 3 Paraganglioma 2/1 65.6 62–69 3.6 3–4.3 No 0/3
Ear 1 Carcinoid 1/0 57 b No 0/1
Adrenal 5 Pheochromocytoma 2/3 54.7 32–71 6.6 5–9 1/5 1/5a
Lung 6 Typical carcinoid 2/4 55.5 37–63 1.9 1.2–3 0/6 0/6
1 Atypical carcinoid 1/0 4 0/1 0/1
Total 29 1/29 (3.4%)
a Nuclear immunoreactivity was weak and focal
b Material examined was represented by bioptic tissues
Table 3 Main clinicopathological features and CDX2 expression in poorly differentiated endocrine carcinomas (PDECs) of different sites.
nk not known
Site n Sex Age (years) Size (cm) Metastases CDX2
Female/male Mean Range Mean Range Primary Metastases
Skin 5 3/2 76.7 52–87 3 2.7–4 2/5 0/5 0/1
Lung 14b 1/13 60 41–75 5.4 1.5–7.8 14/14 1/14c 0/5
Oesophagus/cardias 8 1/7 60 45–73 3.6 2.3–5.5 8/8 1/8a
Stomach 7 0/7 56 38–74 7.6 1.2–14 7/7 1/7a 1/3
Right colon 6 3/3 67.5 50–92 4 2.5–7 6/6 0/6 0/5
Rectum 4 0/4 61 56–67 3.7 1.3–7 3/4 1/4a 1/2
Pancreas 2 1/1 70 61–79 6.5 3–10 2/2 0/2
Prostate 4 0/4 67.7 57–69 d Nk 0/4
Urinary bladder 3 2/1 82 79–86 d Nk 0/3
Total 53 4/53 (7.5%) 2/16 (12.5%)
a All these PDECs contained serotonin-immunoreactive cells
b Nine small cell and five large cell PDECs
c The positive case was a large cell PDEC
d Material examined was represented by bioptic tissues obtained from needle biopsy or transurethral resection
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only a fraction of chromogranin-A-positive intestinal
endocrine cells were CDX2 positive. Using antibodies
directed against specific hormones, it was possible to
demonstrate that CDX2 nuclear staining was present in
all serotonin-immunoreactive (IR) intestinal EC-cells
(Fig. 1A), in about 30% of duodenal GIP (gastric inhib-
itory peptide)-IR cells, in a minority (about 10%) of
duodenal gastrin-IR G-cells (gastrin-producing cells)
(Fig. 1B) and motilin-IR cells. The CDX2 immunostain-
ing was strong in EC-cells, while it was rather weak in G-,
GIP-, and motilin-cells. No CDX2 nuclear staining was
found in somatostatin- (Fig. 1C), cholecystokinin-, se-
cretin- and glicentin-IR intestinal cells. All chromogra-
nin-positive endocrine cells of the stomach, pancreas,
lung, prostate, adrenal gland, thyroid, skin and paragan-
glia were CDX2 negative.
Endocrine tumors
The CDX2 expression in various endocrine GEP tumor
types is summarized in Table 1. Nuclear CDX2 immu-
noreactivity was mainly restricted to midgut EC-cell tu-
mors (19/19 positive cases), in which the majority of cells
were strongly positive (Fig. 2A). A strong CDX2 ex-
pression was also noted in all eight metastases (three
nodal, three liver, two omental) from intestinal EC-cell
WDECs (Fig. 2B, C). In addition, two of three nonfunc-
tioning pancreatic EC-cell tumors showed CDX2-positive
cells, while the three rectal tumors composed of EC-cells
were CDX2 negative. The other GEP WDETs studied (47
cases) were CDX2 negative (Fig. 3), except for one PP-
cell (pancreatic polypeptide-producing cell) tumor and
five gastrinomas, which had a few cells with a weak
CDX2 immunoreactivity. Therefore, considering all non-
midgut GEP tumors, only 8 of 53 (15%) cases showed
CDX2-positive cells; in addition, in these cases, the nu-
clear CDX2 staining was weaker and more focal than that
observed in midgut EC-cell tumors. The six metastases
from non-EC-cell WDECs [three from type-III ECL-cell
(enterochromaffin-like cell) gastric tumors, one from a
duodenal D-cell neoplasm and two from rectal tumors],
such as the primary neoplasms, were completely negative
for nuclear CDX2 expression.
In addition to GEP cases, we investigated the expres-
sion of CDX2 in 29 WDETs and WDECs from different
Table 4 Antibodies and antisera employed. P/M polyclonal/monoclonal
Antibodies/antisera P/M(clone) Dilution Source
Synaptophysin M(snp88) 1:100 BioGenex Laboratories, San Ramon, USA
Neuron-specific enolase M(MIG.N3) 1:100 Monosan San Bio, Am Uden, The Netherlands
Chromogranin A M(PHE5) 1:100 Enzo Diagnostic, New York, USA
Insulin M(AE9D6) 1:200 BioGenex Laboratories
Glucagon P 1:1250 Milab, Malmo, Sweden
Glucagon/glicentin P 1:2500 Milab
Pancreatic polypeptide P 1:4000 Cambridge Research Biochemicals, Cambridge, UK
Somatostatin P 1:500 Dako, Copenhagen, Denmark
Serotonin M(YC5) 1:50 Biogenesis, Bournemouth, UK
C-terminus gastrin-CCK-cerulein M(B4) 1:10000 Farmitalia, Milan, Italy
Secretin P 1:1000 Milab
Motilin P 1:400 Biogenesis
Gastric inhibitory peptide P 1:320 Milab
Vesicular monoamine transporter 2 P 1:500 Chemicon, Tamecula, CA, USA
Peptide YY (PYY) P 1:1000 Biogenesis
CDX2 M(CDX2–88) 1:100 BioGenex
Fig. 1 Double-label immunostainings in duodenal mucosa show
that nuclear CDX2 immunoreactivity (brown) co-localizes with
serotonin in all EC-cells (serotonin-producing cells) (A) and also
with gastrin in G-cells (gastrin-producing cells), although in the
latter the reaction is weaker (B). It is worth noting that only about
10% of gastrin-producing G-cells are CDX2 positive (data not
shown). Nuclei of somatostatin-producing D-cells (somatostatin-
producing cells) are CDX2 negative (C). All hormones are stained
in red, original magnification 200 (A), 400 (B and C)
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sites, including thyroid, parathyroid, carotid body, ear,
adrenal gland and lung (Table 2). With the exception of
one pheochromocytoma showing a few CDX2-positive
nuclei, all tumors were negative.
The expression of CDX2 in 53 PDECs is summarized
in Table 3. Only 3 of 27 (11%) GEP cases, located re-
spectively in the stomach, right colon and rectum, showed
a nuclear CDX2 immunoreactivity in a few cells of both
primary and respective metastases. Among PDECs lo-
cated in organs outside the digestive system, only one
large cell neuroendocrine carcinoma of the lung showed a
few weak CDX2 immunoreactive cells (Fig. 4). The three
GEP tumors presented a component of serotonin-positive
cells, which was lacking in the lung tumor. Metastases
from CDX2-negative primary PDECs (14 cases) were
completely CDX2 negative.
In this study, CDX2 had a specificity of 0.87 and a
sensitivity of 0.90 in detecting intestinal well-differenti-
ated EC-cell tumors. As for the identification of endocrine
tumors expressing serotonin, apart from the tumor site
and cell differentiation, CDX2 had a specificity of 0.93
and a sensitivity of 0.89.
Discussion
In the present study, we have investigated the immuno-
histochemical expression of CDX2 in normal tissues and
in a large series of endocrine neoplasms from different
sites, and we have proved that CDX2 is a good marker of
intestinal EC-cells and related neoplasms.
CDX2 is a transcription factor, which is expressed by
epithelial cells of the intestinal mucosa, playing a role in
their differentiation both in fetal and adult tissues [30].
Although CDX2 expression in exocrine intestinal epi-
thelial cells has been well documented, there are no
previous studies that look at the localization of CDX2
protein in normal intestinal endocrine cells. Our results
demonstrate that CDX2 is expressed in normal human
intestinal endocrine cells and that it shows a specific
distribution among the different intestinal endocrine cell
types. In particular, CDX2 is expressed in all serotonin-
producing intestinal EC-cells and in a small fraction of
duodenal G-, GIP- and motilin-cells but not in other in-
testinal or extra-intestinal endocrine cell types. It is well
known that other transcription factors show a specific
distribution among GEP endocrine cells, and, for several
of them, a role in endocrine cell differentiation has been
Fig. 2 Ileal EC-cell (serotonin-producing cell) tumor shows a dif-
fuse and intense nuclear CDX2 immunoreactivity (A). The lymph-
node (B) and liver (C) and metastases coming from this tumor show
the same pattern of CDX2 expression (original magnification,
200)
Fig. 3 Rectal L-cell (glicentin-producing cell) tumor completely
CDX2 negative (on the left side). Note the internal positive control
in normal epithelial cells of the adjacent mucosa (on the right side)
(original magnification, 400)
Fig. 4 Large cell neuroendocrine carcinoma of the lung showing a
few weak CDX2-positive cells (original magnification 400)
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demonstrated. The factors that have been mostly consid-
ered include neurogenin 3 [11], pax4 and pax6 [16, 28,
29]. The findings of the present study raise the possibility
that the CDX2 protein may play some roles in the regu-
lation of the transcription of multiple intestinal genes,
including those involved in EC-, G-, GIP- and motilin-cell
differentiation.
An interesting approach to verify the role of CDX2 in
the maturation and differentiation of serotonin-producing
EC-cells would be the study of intestinal mucosa in null
mutant cdx2/ mice. Unfortunately, as far as we know,
the endocrine population in cdx2/ null mutant mice has
been never investigated. This has been mainly due to the
fact that the homozygous cdx2/ phenotype is embryo
lethal in the perimplantation period [7]. However, some
studies have been performed in heterozygous cdx2+/
mice that develop polypoid lesions in the pericaecal re-
gion and proximal colon [4]. These polyps showed the
histological features of gastric cardia and body mucosa
and were completely negative for CDX2 expression.
Endocrine cells in these lesions have not been examined.
After the initial hypothesis of the origin of GEP en-
docrine cells from the neural crest [22, 23], chimeric
models have shown a common embryologic origin of gut
endocrine epithelial cells from the endoderm layer [1, 17].
In this context, CDX2 expression in both normal endo-
crine and exocrine intestinal cells and related neoplasms
lends additional support to the hypothesis of the endo-
dermal origin of both these cell types, considering also
that the expression of this transcription factor is restricted
to endoderm-derived tissues.
Our study of the expression of CDX2 in 184 endocrine
tumors has demonstrated that the nuclear immunoreac-
tivity was mainly restricted to GEP WDETs and, in par-
ticular, to midgut EC-cell tumors and to a few gastrin-
producing G-cell neoplasms. These findings are in con-
currence with data reported in recent papers [2, 21, 31]
and in abstracts presented at the 2004 Vancouver USCAP
meeting [3, 14, 18, 19]. All these papers conclude that
CDX2 is mainly expressed by midgut WDETs. Unlike
other studies, in which the functional immunophenotype
has not been fully defined, in the present investigation, we
have clearly demonstrated that, among midgut WDETs,
EC-cell neoplasms of the ileum, appendix and right colon
strongly express CDX2, mirroring the distribution of
CDX2 in normal endocrine cells of the gut. Similarly, we
have proved that CDX2 expression by gastrin-producing
G-cell tumors reflects a biological characteristic of nor-
mal intestinal G-cells but not of gastric G-cells.
We found CDX2 expression in 5 of 24 (20%) pan-
creatic WDETs, represented by 2 gastrinomas and 3
nonfunctioning (2 EC-cell and 1 PP-cell) tumors, with a
correlation of tumor cell type and CDX2 expression
similar to that of intestinal WDETs. Lin et al. [18] did not
find CDX2 immunoreactivity in the 30 pancreatic endo-
crine tumors analyzed, while Barbareschi et al. [3] have
reported CDX2 positivity in 14 of 48 (29%) nonfunc-
tioning pancreatic WDETs, and, interestingly, CDX2-
positive tumors were more frequently found among ma-
lignant cases. In our cases of pancreatic WDETs, we did
not find a similar trend. In the 14 paired samples of pri-
mary and metastatic WDETs analyzed, CDX2 expression
was equal in both sites.
In our cases, intense nuclear positivity was restricted to
metastases from ileal EC-cell tumors. Therefore, CDX2
immunoreactivity in a metastasis from an occult WDEC
should first suggest an ileal origin of the primary neo-
plasm. Considering also that appendiceal EC-cell tumors
are very rarely malignant [6] and that right colon EC-cell
neoplasms are much less frequent than ileal EC-cell tu-
mors, CDX2 immunohistochemistry may, therefore, be
recommended in the study of small specimens of liver or
lymph-node metastases for which the pathologist does not
have sufficient material for an extensive hormonal im-
munoprofile that, in most cases, could help to identify the
primary site of the tumor. It is important to underline that
among GEP tumors, five of six gastrinomas also pre-
sented a CDX2 immunoreactivity. However, the pattern
of CDX2 positivity observed in G-cell tumors was
different from that found in EC-cell neoplasms, being
weaker and focal.
The fact that CDX2 may be used as a marker to
identify intestinal EC-cell neoplasms is also corroborated
by our finding that endocrine tumors that arise outside the
digestive system are CDX2 negative, with the exception
of only one pheochromocytoma showing a focal positiv-
ity. In fact, we did not find any CDX2 immunoreactivity
in lung carcinoids (seven cases) or small cell PDECs (nine
cases). Among five large cell neuroendocrine carcinomas
of the lung, one showed a few weak positive cells. These
findings are in concordance with previously reported data
[2, 3, 18, 21, 31]. As far as we know, there are no reports
of CDX2 expression in non-GEP WDETs other than the
lung, so it is not possible to compare our findings, which
represent the first description demonstrating that endo-
crine tumors located in tissues outside the digestive sys-
tem lack CDX2 immunoreactivity.
Our results prove that CDX2 is a less important marker
of PDECs, being expressed in only four (7.5%) of the
cases examined. Three tumors were located in the di-
gestive system and, as in the majority of WDETs, showed
a component of serotonin-positive cells (Table 3). In
previous studies, some authors [2, 31] investigated small
cell lung carcinomas, and, interestingly, all but one cases
were CDX2-negative. More recently, Barbareschi et al.
[3] have found that 77% of intestinal and 42% of non-
intestinal PDECs were CDX2 positive. The reason for
these differing results is not clear. The low CDX2 ex-
pression that we observed in PDECs can be explained if
one considers that CDX2 is a differentiation factor, im-
portant in maintaining the mature features of endocrine
cells, and its loss may lead to an immature endocrine
pattern. In this context, it is interesting to recall that
CDX2 expression is inversely correlated with the grade of
dysplasia in colorectal adenomas and with the grade of
colorectal carcinomas, being less expressed in poorly
differentiated adenocarcinomas [9].
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In summary, this study demonstrates that CDX2 has a
different expression among different endocrine cell types
of the normal GEP system and among functionally well-
characterized GEP endocrine tumors. CDX2 is expressed
in normal EC-, G-, GIP- and motilin-cells of the intestinal
tract, in all primary and metastatic well-differentiated EC-
cell tumors of the ileum, appendix and right colon and in
a subset of duodenal and pancreatic G-cell and EC-cell
tumors. CDX2 is expressed only focally in PDECs of the
GEP system and is not found in PDECs of other sites.
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